☆ 4.7 Article

Isavuconazole Diffusion in Infected Human Brain

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Volume 63, Issue 10, Pages -

Publisher

AMER SOC MICROBIOLOGY

DOI: 10.1128/AAC.02474-18

Keywords

cerebral aspergillosis; isavuconazole; pharmacokinetic; therapeutic drug monitoring

Categories

Microbiology Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

We report the cases of a 39-year-old woman with chronic lymphocytic leukemia and a 21-year-old man with chronic granulomatous disease treated for cerebral aspergillosis. The patients required radical surgery for infection progression despite adequate isavuconazole plasma concentration or neurological complication. We thus decided to measure the brain isavuconazole concentration. These results suggest that the concentrations of isavuconazole obtained in the infected brain tissue clearly differ from those obtained in the normal brain tissue and the cerebrospinal fluid.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Microbiology

Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis

Chris Kosmidis, Akan Otu, Caroline B. Moore, Malcolm D. Richardson, Riina Rautemaa-Richardson

Summary: Isavuconazole shows promising pharmacokinetic and safety profiles in patients with chronic pulmonary aspergillosis. Lower daily doses may be sufficient to maintain adequate drug levels and lead to better tolerability, enabling long-term therapy continuation.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole

Malene Risum, Mai-Britt Vestergaard, Ulla Moller Weinreich, Marie Helleberg, Nadja Hawwa Vissing, Rene Jorgensen

Summary: This study evaluated the therapeutic drug monitoring of Isavuconazole in the treatment of aspergillosis and mucormycosis. The majority of patients achieved Isavuconazole serum levels within the therapeutic range with lower coefficient of variation compared to patients receiving Voriconazole.

ANTIBIOTICS-BASEL (2021)

Add to Collection

Article Dermatology

Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis

Rainer Hoehl, Ralph Bertram, Martina Kinzig, Golo-Sung Haarmeyer, Matthias Baumgaertel, Arnim Geise, Dorothea Muschner, Doris Prosch, Mira Reger, Hans-Theodor Naumann, Joachim H. Ficker, Jens Kubitz, Joerg Steinmann, Fritz Sorgel

Summary: This study found variations in isavuconazole plasma concentrations in critically ill ICU patients, with significantly lower levels associated with elevated BMI and higher SOFA score, indicating the need for isavuconazole therapeutic drug monitoring in this specific patient population.

MYCOSES (2022)

Add to Collection

Article Medicine, General & Internal

Variability of Isavuconazole Trough Concentrations during Longitudinal Therapeutic Drug Monitoring

Lea Bolcato, Anne Thiebaut-Bertrand, Francoise Stanke-Labesque, Elodie Gautier-Veyret

Summary: Isavuconazole (ISA), a triazole antifungal agent, is used for the treatment of invasive aspergillosis and mucormycosis. Therapeutic drug monitoring (TDM) is crucial for treatment efficacy, and this study investigated the inter- and intra-individual variability of ISA trough concentrations (Cmin) and identified the determinants involved, including dose, aspartate aminotransferase, and protein levels.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Microbiology

Successful Multimodal Therapy with Intracerebral Liposomal Amphotericin B and Systemic High-Dose Isavuconazole in Proven Disseminated Aspergillosis

Simon Feys, Franceska Dedeurwaerdere, Katrien Lagrou, Jeroen Van Lerbeirghe, Dries Deeren

Summary: We present a case of a 32-year-old man receiving chemotherapy for acute B-lymphoblastic leukemia who developed cerebral and pulmonary aspergillosis caused by Aspergillus flavus. Despite systemic antifungal therapy and surgical debridement, the fungal disease progressed, leading to neurological deterioration. Intracerebral administration of liposomal amphotericin B was initiated, resulting in improvement of the cerebral infection. Surgical debridement was necessary for a pleural Aspergillus empyema, and subtherapeutic pleural trough level of isavuconazole was found, prompting an increase in the dose of isavuconazole.

JOURNAL OF FUNGI (2023)

Add to Collection

Article Pharmacology & Pharmacy

Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis

Sacha Sarfati, Julien Wils, Timothee Lambert, Celine Mory, Laurent Imbert, Gilles Gargala, Helene Morisse-Pradier, Fabien Lamoureux

Summary: This study evaluated the feasibility and utility of therapeutic drug monitoring (TDM) of voriconazole concentration in sputum for patients treated for pulmonary aspergillosis. The results showed a correlation between sputum and plasma levels of voriconazole, and an equation was established to predict voriconazole concentration in plasma from sputum.

PHARMACEUTICS (2022)

Add to Collection

Article Microbiology

Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis

Irina Ullmann, Andrea Aregger, Stephen L. Leib, Stefan Zimmerli

Summary: Treatment options for cerebral aspergillosis are limited. This study found potentially therapeutically relevant concentrations of caspofungin in brain tissue and prolonged survival in caspofungin-treated animals using a rat model. Further studies are needed to confirm the efficacy of caspofungin as a treatment option for cerebral aspergillosis.

MICROBIOLOGY SPECTRUM (2022)

Add to Collection

Article Infectious Diseases

Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation

Lisa Kriegl, Stefan Hatzl, Christoph Zurl, Alexander Christian Reisinger, Gernot Schilcher, Philipp Eller, Yvonne Gringschl, Tina Muhr, Andreas Meinitzer, Juergen Prattes, Martin Hoenigl, Robert Krause

Summary: This study found that ECMO therapy may influence isavuconazole plasma concentrations, but not altered by the ECMO oxygenator. Patients achieved median plasma concentrations >1 μg/mL 24 hours after the first loading dose.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Chronopharmacology in Therapeutic Drug Monitoring-Dependencies between the Rhythmics of Pharmacokinetic Processes and Drug Concentration in Blood

Lukasz Dobrek

Summary: The optimization of pharmacotherapy aims for maximum individualization to ensure effectiveness and safety for the patient. Factors such as patient characteristics, polypharmacotherapy, genotyping, and TDM monitoring are crucial considerations. Chronopharmacology is also an important but often overlooked factor in drug therapy.

PHARMACEUTICS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?

Pier Giorgio Cojutti, Alessia Carnelutti, Davide Lazzarotto, Emanuela Sozio, Anna Candoni, Renato Fanin, Carlo Tascini, Federico Pea

Summary: The study aimed to analyze the pharmacokinetics and pharmacodynamics of isavuconazole in hospitalized patients, showing that the efficacy of isavuconazole at standard maintenance doses is sustained and safe, without the need for adjustment based on clinical variables, and not requiring therapeutic drug monitoring like voriconazole and posaconazole.

PHARMACEUTICS (2021)

Add to Collection

Article Chemistry, Medicinal

Individualized Vancomycin Dosing with Therapeutic Drug Monitoring and Pharmacokinetic Consultation Service: A Large-Scale Retrospective Observational Study

Sang-Mi Kim, Hyun-Seung Lee, Na-Young Hwang, Kyunga Kim, Hyung-Doo Park, Soo-Youn Lee

Summary: In non-critically ill patients, utilizing PK-guided dosing through PKCS led to a higher target attainment rate of vancomycin but did not reduce treatment failures, shorten treatment duration, or decrease nephrotoxicity in vancomycin therapy. More selective criteria for individualized pharmacokinetic-guided dosing are needed due to the excessive efforts currently put into vancomycin dosing and monitoring.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Add to Collection

Article Dermatology

Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19

Ralph Bertram, Hans-Theodor Naumann, Vanessa Bartsch, Wolfgang Hitzl, Martina Kinzig, Golo-Sung Haarmeyer, Matthias Baumgaertel, Arnim Geise, Dorothea Muschner, Jens Nentwich, Stefan John, Fritz Soergel, Joerg Steinmann, Rainer Hoehl

Summary: This study aimed to determine the plasma concentrations of isavuconazole in ICU patients with COVID-19 and invasive fungal infection, and evaluate the factors contributing to sub-therapeutic drug levels. The results showed that patients' risk factors and supportive therapies can negatively affect the plasma levels of isavuconazole.

MYCOSES (2023)

Add to Collection

Article Pharmacology & Pharmacy

Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure

Kenneth H. Wills, Stephen J. Behan, Michael J. Nance, Jessica L. Dawson, Thomas M. Polasek, Ashley M. Hopkins, Madele van Dyk, Andrew Rowland

Summary: This study verifies the importance of covariates identified in a prior clozapine population pharmacokinetic model and demonstrates that pharmacokinetic modeling can be used as an adjunct to therapeutic drug monitoring to deconvolute sources of variability in clozapine exposure. Age, metabolic activity, sex, and weight were found to be important physiological covariates associated with variability in clozapine concentrations.

PHARMACEUTICS (2022)

Add to Collection

Article Microbiology

New Perspectives on Antimicrobial Agents: Isavuconazole

James S. Lewis, Nathan P. Wiederhold, Morgan Hakki, George R. Thompson

Summary: Isavuconazole is a newly available antifungal drug that is effective against various fungi. It is FDA-approved for the treatment of invasive aspergillosis and mucormycosis. Isavuconazole has significant advantages over other antifungal drugs, such as lack of QTc interval prolongation, more predictable pharmacokinetics, a simpler drug interaction profile, and improved tolerability.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

In Silico Pharmacokinetic Study of Vancomycin Using PBPK Modeling and Therapeutic Drug Monitoring

Abigail Ferreira, Helena Martins, Jose C. Oliveira, Rui Lapa, Nuno Vale

Summary: This study analyzed clinical information of patients in a hospital in Porto, Portugal and developed physiologically based pharmacokinetic (PBPK) models to study the influence of different dosages and treatment regimens of vancomycin, as well as the impact of age, weight, and renal function on its pharmacokinetics. The results showed a linear effect of dose and significant influence of weight and renal function on plasmatic levels of vancomycin, highlighting the importance of therapeutic monitoring and demonstrating the usefulness of in silico tools such as PBPK modeling.

CURRENT DRUG METABOLISM (2021)

Add to Collection

Article Infectious Diseases

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, Alpha Diallo, Minh-Patrick Le, Gilles Peytavin, Therese Staub, Richard Greil, Jeremie Guedj, Jose-Artur Paiva, Dominique Costagliola, Yazdan Yazdanpanah, Charles Burdet, France Mentre

Summary: A study conducted in COVID-19 patients admitted to hospital and requiring oxygen support found that remdesivir did not show significant clinical benefits compared to standard care alone.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Progressive multifocal leukoencephalopathy in patients with immunovirological control and at least 6 months of combination antiretroviral therapy

Paul Dalla-Pozza, Maxime Hentzien, Clotilde Allavena, Anne Doe de Maindreville, Kevin Bouiller, Marc-Antoine Valantin, Emmanuel Lafont, Olivia Zaegel-Faucher, Antoine Cheret, Guillaume Martin-Blondel, Laurent Cotte, Firouze Bani-Sadr

Summary: This study highlights that factors other than low CD4(+) cell count and high HIV viral load may be associated with the occurrence of PML in people with HIV. Further studies are warranted to investigate in greater detail the immunologic characteristics of people with HIV who develop PML despite immune-virological control.

AIDS (2022)

Add to Collection

Article Infectious Diseases

Cerebral aspergillosis in the era of new antifungals: The CEREALS national cohort study Nationwide CEREbral Aspergillosis Lesional study (CEREALS)

A. Serris, J. Benzakoun, F. Danion, R. Porcher, R. Sonneville, M. Wolff, S. Kremer, V Letscher-Bru, A. Fekkar, G. Hekimian, V Pourcher, M-E Bougnoux, S. Poiree, F. Ader, F. Persat, Francois Cotton, Pierre Tattevin, J-P Gangneux, L. Lelievre, S. Cassaing, Fabrice Bonneville, S. Houze, Stephane Bretagne, R. Herbrecht, O. Lortholary, O. Naggara, F. Lanternier

Summary: This study retrospectively analyzed 119 cases of cerebral aspergillosis and identified two distinct disease patterns, hematogenous dissemination and contiguous dissemination, based on the route of spread. Hematogenous dissemination was associated with impaired consciousness, multiple abscesses, and microangiopathy, while contiguous dissemination was associated with cranial nerve palsy and evidence of meningitis. Hematogenous dissemination, hematological malignancy, and detection of serum galactomannan were associated with higher six-week mortality.

JOURNAL OF INFECTION (2022)

Add to Collection

Article Cell Biology

Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort

Raphael Carapito, Richard Li, Julie Helms, Christine Carapito, Sharvari Gujja, Veronique Rolli, Raony Guimaraes, Jose Malagon-Lopez, Perrine Spinnhirny, Alexandre Lederle, Razieh Mohseninia, Aurelie Hirschler, Leslie Muller, Paul Bastard, Adrian Gervais, Qian Zhang, Francois Danion, Yvon Ruch, Maleka Schenck, Olivier Collange, Thien-Nga Chamaraux-Tran, Anne Molitor, Angelique Pichot, Alice Bernard, Ouria Tahar, Sabrina Bibi-Triki, Haiguo Wu, Nicodeme Paul, Sylvain Mayeur, Annabel Larnicol, Geraldine Laumond, Julia Frappier, Sylvie Schmidt, Antoine Hanauer, Cecile Macquin, Tristan Stemmelen, Michael Simons, Xavier Mariette, Olivier Hermine, Samira Fafi-Kremer, Bernard Goichot, Bernard Drenou, Khaldoun Kuteifan, Julien Pottecher, Paul-Michel Mertes, Shweta Kailasan, M. Javad Aman, Elisa Pin, Peter Nilsson, Anne Thomas, Alain Viari, Damien Sanlaville, Francis Schneider, Jean Sibilia, Pierre-Louis Tharaux, Jean-Laurent Casanova, Yves Hansmann, Daniel Lidar, Mirjana Radosavljevic, Jeffrey R. Gulcher, Ferhat Meziani, Christiane Moog, Thomas W. Chittenden, Seiamak Bahram

Summary: In this study, multi-omics analysis and artificial intelligence were used to examine the differences in biological factors between critical and non-critical COVID-19 patients in a young and otherwise healthy cohort. The study identified ADAM9 as a driver of disease severity and a potential therapeutic target.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Immunology

Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly Complication

Francois Danion, Valerie Letscher-Bru, Juliette Guitard, Karine Sitbon, Sarah Delliere, Adela Angoulvant, Guillaume Desoubeaux, Francoise Botterel, Anne-Pauline Bellanger, Gilles Gargala, Fabrice Uhel, Marie-Elisabeth Bougnoux, Victor Gerber, Justin Michel, Marjorie Cornu, Stephane Bretagne, Fanny Lanternier

Summary: We reported 17 cases of COVID-19 associated mucormycosis in France and compared them to India, finding significant differences in the frequencies of diabetes mellitus, hematological malignancies, anatomical sites, and mortality.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Article Rheumatology

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

France X. Mariette, O. Hermine, P-L Tharaux, M. Resche-Rigon, R. Porcher, P. Ravaud

Summary: Treatment with sarilumab did not improve early outcomes in patients with moderate-to-severe COVID-19 pneumonia. Further studies are warranted to evaluate the effect of sarilumab on long-term survival.

LANCET RHEUMATOLOGY (2022)

Add to Collection

Article Immunology

Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality

Francis Schneider, Pierrick Le Borgne, Jean-Etienne Herbrecht, Francois Danion, Morgane Solis, Sophie Helle, Cosette Betscha, Raphael Clere-Jehl, Francois Lefebvre, Vincent Castelain, Yannick Goumon, Marie-Helene Metz-Boutigue

Summary: Neuroendocrine cells release Catestatin (CST) from Chromogranin A (CgA) to regulate stress responses, and COVID patients with higher plasma CST levels may have an increased risk of in-hospital mortality. The study suggests that plasma CST could be a potential biomarker for predicting outcomes in COVID patients.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Microbiology

Incidence and Time-to-Onset of Carbapenemase-Producing Enterobacterales (CPE) Infections in CPE Carriers: a Retrospective Cohort Study

B. Hoellinger, S. Deboscker, F. Danion, T. Lavigne, F. Severac, Y. Ruch, A. Ursenbach, N. Lefebvre, P. Boyer, Y. Hansmann

Summary: This study found a high incidence of CPE infections in CPE carriers, which occurred earlier than other infections and led to a high mortality rate in a short period of time. A history of neurological disease was the only risk factor associated with CPE infections in CPE carriers.

MICROBIOLOGY SPECTRUM (2022)

Add to Collection

Letter Infectious Diseases

Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series

Baptiste Hoellinger, Celestine Simand, Katy Jeannot, Carlos Garijo, Mircea Cristinar, Fanny Reisz, Francois Danion, Axel Ursenbach, Nicolas Lefebvre, Pierre Boyer, Yves Hansmann, Antoine Studer, Frederic Schramm, Yvon Ruch

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Add to Collection

Review Microbiology

What Is New in Pulmonary Mucormycosis?

Francois Danion, Anne Coste, Coralie Le Hyaric, Clea Melenotte, Frederic Lamoth, Thierry Calandra, Dea Garcia-Hermoso, Vishukumar Aimanianda, Fanny Lanternier, Olivier Lortholary

Summary: Mucormycosis is a rare and life-threatening fungal infection caused by molds of the order Mucorales. It mainly affects the lungs, following the rhino-orbito-cerebral (ROC) areas and the skin. Risk factors for pulmonary mucormycosis (PM) include hematological malignancies and solid organ transplantation, while ROC infections are commonly associated with diabetes mellitus. The diagnosis of PM relies on CT scans, cultures, PCR tests, and histology, and treatment involves liposomal amphotericin B as the first-line therapy.

JOURNAL OF FUNGI (2023)

Add to Collection

Article Critical Care Medicine

Improving Diagnosis of Pulmonary Mucormycosis Leads From a Contemporary National Study of 114 Cases

Anne Coste, Anne Conrad, Raphael Porcher, Sylvain Poiree, Pierre Peterlin, Claire Defrance, Valerie Letscher-Bru, Florent Morio, Thomas Gastinne, Marie-Elisabeth Bougnoux, Felipe Suarez, Gilles Nevez, Damien Dupont, Florence Ader, Carine Halfon-Domenech, Sophie Ducastelle-Lepretre, Francoise Botterel, Laurence Millon, Gaelle Guillerm, Severine Ansart, David Boutoille, Marie-Pierre Ledoux, Jean-Etienne Herbrecht, Christine Robin, Giovanna Melica, Francois Danion, Elodie Blanchard, Olivier Paccoud, Dea Garcia-Hermoso, Olivier Lortholary, Raoul Herbrecht, Fanny Lanternier

Summary: This study retrospectively reviewed 114 cases of pulmonary mucormycosis (PM) from six French teaching hospitals between 2008 and 2019. The study found that neutropenia and radiologic findings influence the disease presentation and contribution of diagnostic tools. Serum quantitative polymerase chain reaction (qPCR) is more contributive in patients with neutropenia, while bronchoalveolar lavage (BAL) is more contributive in patients without neutropenia.

CHEST (2023)

Add to Collection

Article Mycology

Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study

Matthias Egger, Jon Salmanton-Garcia, Aleksandra Barac, Jean-Pierre Gangneux, Helene Guegan, Valentina Arsic-Arsenijevic, Tadeja Matos, Rok Tomazin, Nikolai Klimko, Matteo Bassetti, Helena Hammarstroem, Eelco F. J. Meijer, Jacques F. Meis, Juergen Prattes, Robert Krause, Oguz Resat Sipahi, Ulrike Scharmann, P. Lewis White, Guillaume Desoubeaux, Julio Garcia-Rodriguez, Carolina Garcia-Vidal, Sonia Martin-Perez, Maite Ruiz, Mario Tumbarello, Alida Fe Talento, Benedict Rogers, Katrien Lagrou, Jens van Praet, Sevtap Arikan-Akdagli, Maiken C. Arendrup, Philipp Koehler, Oliver A. Cornely, Martin Hoenigl

Summary: This sub-analysis of the Candida III study investigated the demographical and clinical characteristics of patients with candidemia who required prolonged hospitalization for completion of intravenous antifungal treatment. The study found that the use of initial echinocandin treatment was associated with prolonged hospital stay, while factors such as neutropenia, intensive care unit admission, catheter related candidemia, total parenteral nutrition, and C. parapsilosis infection were associated with shorter hospitalization.

MYCOPATHOLOGIA (2023)

Add to Collection

Article Immunology

Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial

Benjamin Gaborit, Bernard Vanhove, Karine Lacombe, Thomas Guimard, Laurent Hocqueloux, Ludivine Perrier, Vincent Dubee, Virginie Ferre, Celine Bressollette, Regis Josien, Aurelie Le Thuaut, Marie-Anne Vibet, Alexandra Jobert, Eric Dailly, Florence Ader, Sophie Brouard, Odile Duvaux, Francois Raffi, POLYCOR Study Grp

Summary: The study evaluated the safety and efficacy of XAV-19, an antispike glyco-humanized swine polyclonal neutralizing antibody, in patients hospitalized with severe COVID-19. The results showed that a single intravenous dose of XAV-19 did not significantly differ from placebo in terms of disease progression at day 15 for patients requiring low-flow oxygen therapy.

OPEN FORUM INFECTIOUS DISEASES (2023)

Add to Collection

Letter Infectious Diseases

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, France Mentre, Charles Burdet

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Fungal Infections Caused by Kazachstania spp., Strasbourg, France, 2007-2020

Charlotte Kaeuffer, Mathieu Baldacini, Tiffany Ruge, Yvon Ruch, Yves-Jean Zhu, Manon De Cian, Guillaume Philouze, Philippe Bachellier, Julie Denis, Nicolas Lefebvre, Francis Schneider, Yves Hansmann, Valerie Letscher-Bru, Raoul Herbrecht, Marcela Sabou, Francois Danion

Summary: Rare cases of fungal infections caused by Kazachstania (Arxiozyma) spp. were analyzed in a hospital in Strasbourg, France. The study found that some patients had proven fungal disease, while others were colonized by the fungus. The strains tested showed resistance to fluconazole.

EMERGING INFECTIOUS DISEASES (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.